Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Adult, Obesity-related, Symptomatic Asthma
NCT05254314Phase 2Active, not recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Oct 2022
- Primary completion
- Sep 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Study Drug (Semaglutide) with Placebo (2 arms). Primary endpoints: Asthma Control Questionnaire-7 at 12 weeks and Serum periostin level at 4 weeks. Started Oct 2022; status: active, not recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05254314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05254314.